Aptose Biosciences (APTO) has provided an update.
In a significant development, the Registrant announced through a press release on March 18, 2024, that the disclosed information will not be considered as filed under the Securities Exchange Act of 1934. Moreover, this information won’t be automatically included in other filings unless specifically referenced, ensuring clarity for stakeholders and maintaining compliance with regulatory guidelines.
For an in-depth examination of APTO stock, go to TipRanks’ Stock Analysis page.
